Software giant Oracle and decentralized clinical trial company ObvioHealth are joining forces to support a speedier exchange of data collected from trials in the Asia-Pacific region.
The collaboration will be focused on quickly collecting, integrating and analyzing multisource data generated from trial sites, patients, devices and laboratories, ObvioHealth said in an Oct. 25 press release. Financial terms of the partnership weren’t disclosed.
"Because [decentralized clinical trials] are designed to be more convenient for patients, they naturally involve more complex sources of data—physical sites, electronic health records, wearables and mobile apps—and Oracle's technology provides us with a unified environment to bring all of that data together in one place," ObvioHealth CEO Ivan Jarry said in the release.
The partnership follows in the wake of ObvioHealth’s launch of its latest decentralized trials platform and mobile app dubbed ObvioGo. The platform fully integrates with Oracle’s Clinical One Cloud Service, providing pharma-grade analytics and reporting "critical to delivering timely patient insights," according to the release.
Back in May, ObvioHealth rolled out artificial-intelligence-based technologies designed to remove subjectivity from data collection and assessment in clinical trials involving children. The technologies, called the pediatric GI instrument and the pediatric cry capture instrument, aim to make data capture easier for caregivers and children while facilitating the scoring of unstructured data by expert assessors.